

PHARMACEUTICAL DEVELOPMENT

	VII
Acronyms - Abbreviations	XIII
Introduction	XIV
Preface	XV
Forward	XVI
Chapter 1	
Regulatory	1.1
- Pre-formulation checklist	1.3
D ocumentation	
- The Big Picture	1.4
- SOP control and checklist	1.5
Development Notebooks	1.6
- Development Notebooks checklist	1.7
- SOP Control and Development Notebooks SOPs	1.8
Objection 0	
Chapter 2	
	2.1
Developing the Formula -an Overview - Formulation checklist	2.1 2.2
D eveloping the Formula -an Overview	
Developing the Formula -an Overview - Formulation checklist	2.2
Developing the Formula -an Overview - Formulation checklist - Formula Development	2.2 2.3
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist	2.2 2.3 2.4
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs	2.2 2.3 2.4 2.5
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs Biopharmaceutical guidance	2.2 2.3 2.4 2.5 2.6
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs Biopharmaceutical guidance Developing the Formula Product Development Flow Chart	2.2 2.3 2.4 2.5 2.6 2.7
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs Biopharmaceutical guidance Developing the Formula	2.2 2.3 2.4 2.5 2.6 2.7 2.13
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs Biopharmaceutical guidance Developing the Formula Product Development Flow Chart Product Development Guide	2.2 2.3 2.4 2.5 2.6 2.7 2.13 2.15
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs Biopharmaceutical guidance Developing the Formula Product Development Flow Chart Product Development Guide Softgel Capsule Development	2.2 2.3 2.4 2.5 2.6 2.7 2.13 2.15 2.23
Developing the Formula -an Overview - Formulation checklist - Formula Development Drug Development Checklist Development Formula SOPs Biopharmaceutical guidance Developing the Formula Product Development Flow Chart Product Development Guide Softgel Capsule Development Softgel Flow Charts	2.2 2.3 2.4 2.5 2.6 2.7 2.13 2.15 2.23 2.32



Chapter 2	
Purified Water - an essential ingredient	2.39
Do and Don'ts in Development	2.42
Purified Water - Checklist	2.43
Chapter 3	
Active Ingredients	3.1
- Do's and Don'ts	3.2
Active checklistApproved Suppliers Checklist	3.3 3.5
- Standard Operating Procedures, Actives	3.6
Chapter 4	0.0
Semi active ingredients	4.1
-Validating the Semi-active ingredients, Checklist	4.1
Qualifying the Antioxidant	4.4
Antioxidant Tabulations	4.5
Thioxidant rabulations	1.0
Chapter 5	
Non active materials (excipients)	5.1
-Checklist non active ingredient	5.3
-Standard Operating Procedures, Non actives	5.4
Chapter 6	
Container closure systems	6.1
- Container-liner-closure systems, checklist	6.2
- Container-liner-closure systems, SOPs	6.4
- Packaging Components	6.5
- Packaging Components Documentation Requirements SOP	6.6
Packaging CharacteristicsPackaging Component Descriptions	6.11 6.12
- Packaging Component	6.16
Chapter 7	00
Manufacturing Instructions	7.1
- Manufacturing Instructions; checklist	7.4
- The manufacturing Instructions and Controls	7.5
- Manufacturing Flow Charts	7.11
- Large scale manufacturing Instructions	7.14
- Large scale Master Formula	7.18
- Large scale Manufacturing Instructions	7.22



Chapter 8	
In-process Quality Controls	8.1
- Manufacturing in-process controls; checklist	8.2
- In-process Specifications - overview	8.5
- In-process Specifications - production	8.6
- In-process Control Specifications - quality control	8.7
- In-process SOPs - Quality Control Chapter 9	8.8
Finished Product Specifications	9.1
- Finished Product Specifications - Release	9.2
- Finished Product Specifications; - Stability	9.3
- Finished Product Specifications; Required Checklist & SOPs	9.5
The state of the s	9.0
Chapter 10	
Process Optimization and Procedures	10.1
Qualification of Antioxidant Qualification of Limits	10.2 10.3
	10.3
Chapter 11	
Scale-up Procedures	11.1
Scale-up Procedures - wet granulation	11.2
Scale-up Procedures - Encapsulation	11.4
- Scale-up procedures; checklist	11.6
- Scale-up procedures; SOPs	11.7
Scale-up Protocol - Fill Material	11.8
Scale-up Flow Chart	11.14
Chapter 12	
Cleaning Procedures and Guidelines	12.1
Cleaning Limits; Checklists	12.6
Cleaning Validation Requirements; SOPs	12.8
Chapter 13	
Analytical Validation Requirements	13.1
- Analytical Testing Out of Specification	13.21
- Analytical Testing Do's and Don'ts - Retesting Rules	13.23
Out-of-Specifications ChecklistsRuggedness and Robustness	13.24 13.37
- Impurities in Drug Substances	13.41
- Impurities Do's and Don'ts	13.50
- Impurities Glossary of terms	13.51
- Impurities Decision Trees	13.53
Analytical Validation Definitions	13.68
Analytical Post approval Changes -PAC-ALTS	13.81



Chapter 14

Process Qualification Batch	14.1
- Process Qualification Batch; Checklist	14.2
- Process Qualification Batch; SOPs	14.3
- Process Qualification Blend Analysis & Do's and Don'ts	14.5
- Process Qualification - Encapsulation process	14.9
Prospective process Qualification Protocol	14.11
Process Qualification Flow Charts	14.20

Chapter 15

Pivotal batch

- The Pivotal Batch	15.1
- Pivotal batch Checklist	15.2
- Pivotal batch SOPs	15.3
- Sampling and Testing the Pivotal Batch	15.5
- Auditing the Pivotal batch	15.11
- Auditing the Pivotal batch Checklist	15.13

Chapter 16

Bioequivalence vs. RLD	16.1
Test Designs - Overview	16.2
Statistical Bioequivalence	16.13
IBE Equation explained	16.14
IBE - Big Picture (Pros and Cons)	16.15
Comparing IBE and ABE	16.16
Dissolution Testing in IR Dosage Forms	16.18
Typical IVIVC Models	16.21
Choosing IVIVC levels	16.22
Dissolution Testing in IR Solid Dosage Forms	16.25
Similarity Factor in dissolution testing & Biowaivers	16.30
Overall Dissolution Picture	16.35
Biopharmaceutics Classification System	16.36
Evaluating Differences between Drug, Powder Blend, and Capsules	16.37
Performance Verification in Dissolution testing	16.39
Bioavailability and Bioequivalence - General Considerations	16.55
Food-Effects in BA-BE Studies	16.81
Dissolution Testing of Solid Oral Dosage Forms	16.101
Biopharmaceutical Classification System - BCS	16.105
Similarity Testing - Chow, Pitt and Others	16.115



Chapter 17	
Technical Transfer Documentation	17.1
- Technical Transfer Documentation; Checklist	17.6
- Technical Transfer Documentation; Pharmaceutical Part	17.9
- Technical Transfer Documentation; Analytical Part	17.13
Chapter 18	
Process Validation Batches	18.1
- The Process Validation Batches; Checklist	18.2
- Process Validation Requirements; SOPs	18.4
Process Validation Master PlansProcess Optimization Flowchart	18.5 18.7
- 1 Todess Optimization Flowchart	10.7
Chapter 19	
PreApproval Inspections	19.1
PAI Summary	19.9
PreApproval Inspection Audit - Team Set Up	19.10
PreApproval Inspection Audit - Team Activities	19.11
Chapter 20	
Stability Testing of Drug Substance and Drug Product - overview	20.1
Stability Testing of Drug Substance and Drug Product - ANDAs	20.15
Stability Testing Significant Change	20.21
Significant Change SOP	20.25
Stability Storage Conditions	20.29
Photostability in Drug Substances	20.31
Setting up a Functional Stability Unit	20.40
Stability SOPs Development	20.48
Chapter 21	
Standard Operational Procedures	
Development SOPs	21.1
Index of Pharmaceutical Standard Operating Procedures	21.3
Index of Analytical Standard Operating Procedures	21.10
Index of Microbiological Standard Operating Procedures	21.16
Index of Stability Standard Operating Procedures	21.20

ISSN 0793 8756

An on-going series

Additional Volumes in Preparation
ISBN 0793 8640 - Electronic Version
Handbook Development 24 Volume Series
ISSN Series Number 0793 7792 - Electronic Version



Handbook of Generic Development - Oral Capsule Dosage Form


This handbook represents the new International Edition of the ongoing 24 volume series of Generic Drug Development and appears under the cumulative title of the Handbook series of Generic Drug Development. The ongoing series is updated annually at the end of each year. This is an ongoing process as new data, specifications and process techniques are added on a continual and expanding basis. This handbook is fact, never fully complete, as each new annual edition brings an enlarged and extended profile in the drug development process, as well as new agency rules, guidelines and guidance to industry which continue to be added year by year as the global product data base expands. Currently over 150 scientific publications and drug development conferences are annually referenced in the extended 24 volume Handbook series of Generic Drug Development.

This mammoth task presents a continual ongoing commitment by the scientific review committee to the improvement of the technical databases and the product specific drug development requirements and know-how technology accessed through the world wide IAGIM joint ventures and know-how projects currently active in over 15 countries.

The Handbook is available in electronic format (Online and CD ROM) and the e-format is up-dated annually to association members of IAGIM.

This international edition of the Handbook has been enlarged and updated to meet the latest Guidance for Industry - Organization of an Abbreviated New Drug Application as well as all current approved and key *draft* FDA guideline requirements of the Center of Drug Evaluation and Research (CDER) up to the publishing date.

Editorial Advisory Board.



Additional Volumes in Preparation
General Drug Development Series ISSN 0973 7601
Electronic Drug Development Series ISSN 0973 761X

ÓŠ Î
International Edition
ppp
© COPYRIGHT - LOCUM PRESS
Ï > Đ